Genzyme, a Sanofi company (SNY), Gets Green Light for Its AUBAGIO(R) in Australia for Treatment of R
11/23/2012

** Genzyme, a SNY company (NYSE:SNY), reported that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO(R) (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

Online PR News – 23-November-2012 – Las Vegas, NV – SNY, Sanofi

Genzyme, a SNY company, reported that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO(R) (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September. AUBAGIO is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for AUBAGIO is not fully understood, it may involve a reduction in the number of activated lymphocytes in the central nervous system. SNY's Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years SNY discovers, develops and distributes therapeutic solutions focused on patients’ needs. SNY has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. More about SNY at www.sanofi-aventis.com

Read full disclaimer at http://pennygovernance.com/disclaimer